SEARCH

SEARCH BY CITATION

References

  • 1
    The Magpie Trial Collaboration G. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial. Lancet 2002;359(9321):18771890.DOI: 10.1016/S0140-6736(02)08778-0
  • 2
    Department of Health WO, Scottish Home and Health Department, Department of Health and Social Security, Northern Ireland. Why Mothers Die. Report on Confidential Inquiries into Maternal Deaths in the United Kingdom 1997–1999. London: HMSO, 2001.
  • 3
    Department of Health WO, Scottish Home and Health Department, Department of Health and Social Security, Northern Ireland. Why Mothers Die. Report on Confidential Inquiries into Maternal Deaths in the United Kingdom 1994–96. London: HMSO, 1999.
  • 4
    Jankowicz D, Tuffnell DJ. Managing pre-eclampsia 1: establishing guidelines. Br J Midwifery 2004;12(11):687691 (November).
  • 5
    Tuffnell DJ, Currie I, Bickford Smith P, Wilkinson K, Jones SE. A complete audit cycle of management of severe pre-eclampsia 1990–1992. Contemp Rev Obstet Gynaecol 1994;6: 3640.
  • 6
    Douglas KA, Redman CWG. Eclampsia in the United-Kingdom. BMJ 1994;309: 13951400.
  • 7
    Walker JJ, Greer I, Calder AA. Treatment of acute pregnancy-related hypertension: labetalol and hydralazine compared. Postgrad Med J 1983;59(Suppl 3):168170.
  • 8
    Magee LA, Ornstein MP, von Dadelszen P. Fortnightly review: management of hypertension in pregnancy. BMJ 1999;318(7194):13321336.
  • 9
    Douglas K, Redman C. Eclampsia in the United Kingdom. The ‘BEST’ way forward. Br J Obstet Gynaecol 1992;99: 355359.
  • 10
    The Eclampsia Trial Collaborative Group. Which anticonvulsant for women with eclampsia—evidence from the collaborative eclampsia trial. Lancet 1995;345: 14551463.
  • 11
    Mehta NJ, Mehta RN, Khan IA. Peripartum cardiomyopathy: clinical and therapeutic aspects. Angiology 2001;52(11):759762.
  • 12
    Visser W, Wallenburg HC. Maternal and perinatal outcome of temporizing management in 254 consecutive patients with severe pre-eclampsia remote from term. Eur J Obstet Gynecol Reprod Biol 1995;63(2):147154.
  • 13
    Duley L, Williams J, Henderson-Smart DJ. Plasma volume expansion for treatment of women with pre-eclampsia. Cochrane Database Syst Rev 2000;(2):CD001805.
  • 14
    Gilson GJ, Kramer RL, Barada C, Izquierdo LA, Curet LB. Does labetalol predispose to pulmonary edema in severe pregnancy-induced hypertensive disease? J Matern Fetal Med 1998;7(3):142147.
  • 15
    Bolte AC, Dekker GA, van Eyck J, van Schijndel RS, van Geijn HP. Lack of agreement between central venous pressure and pulmonary capillary wedge pressure in preeclampsia. Hypertens Pregnancy 2000;19(3):261271.
  • 16
    Sibai BM, Ramadan MK, Usta I, Salama M, Mercer BM, Friedman SA. Maternal morbidity and mortality in 442 pregnancies with hemolysis, elevated liver enzymes, and low platelets (HELLP syndrome). Am J Obstet Gynecol 1993;169(4):10001006 [see comments].
  • 17
    Martin Jr JN, May WL, Magann EF, Terrone DA, Rinehart BK, Blake PG. Early risk assessment of severe preeclampsia: admission battery of symptoms and laboratory tests to predict likelihood of subsequent significant maternal morbidity. Am J Obstet Gynecol 1999;180(6 Pt 1):14071414.
  • 18
    Drakeley AJ, Le Roux PA, Anthony J, Penny J. Acute renal failure complicating severe preeclampsia requiring admission to an obstetric intensive care unit. Am J Obstet Gynecol 2002;186(2):253256.
  • 19
    Panchal S, Arria AM, Harris AP. Intensive care utilization during hospital admission for delivery: prevalence, risk factors, and outcomes in a statewide population. Anesthesiology 2000;92(6):15371544.